Acceleron Pharma Q1 FY21: revenue $24.8M, up 470%

Key figures from this report

These are the numbers Acceleron Pharma reported for Q1 FY21, the quarter ended Mar 31, 2021, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

1. Revenue$24.8M+470% from $4.3M in Q1 FY2010-Q income statement, on EDGAR
2. Net income−$63.5MAgainst −$50.9M in Q1 FY2010-Q income statement, on EDGAR
3. Cash and cash equivalents$455.5M+64% from $277.5M in Q1 FY20Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
4. Cash from operations−$67.9MAgainst −$46.5M in Q1 FY2010-Q cash flow statement, on EDGAR